A Phase 3 interventional study of Daridorexant 10 mg and Daridorexant 25 mg in Insomnia Disorder, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 106 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.
Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 4th largest by enrollment, is one of 3 that started in 2018, is one of 5 in phase 3, and was the 6th registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 40–62 · Women only
University Hospital, Montpellier · Sites in France
Ages 60–85
Sterling McPherson · Sites in United States
Ages 18+
Xuanwu Hospital, Beijing · Sites in China
Ages 18–70
Institut d'Investigació Biomèdica de Bellvitge · Sites in Spain
Ages 18–99
By country, each count listing its studies:
daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2018.
This study's enrollment of 804 is above the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 165 across the 16 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 9 most frequent:
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd.: none open now, 1 under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd., this one is one of 3 that started in 2018, is one of 3 in phase 3, and was the 7th registered.
Idorsia Pharmaceuticals Ltd.’s Sleep Initiation and Maintenance Disorders studies by the year they started, since 2015.
3 of the studies testing daridorexant in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07328594Legacy Health SystemImpact of Daridorexant on Sleep, Daytime Alertness, and Smoking | 2027-03-31 |
| NCT07555743Institut d'Investigació Biomèdica de BellvitgeEfficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia | 2027-04 |
| NCT05924425University Hospital, MontpellierDaridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease | 2027-05-13 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Idorsia Pharmaceuticals Ltd.’s 11 in Sleep Initiation and Maintenance Disorders:
This tab as a report to print or save as PDF → With an account.
Study to assess the long term safety and tolerability of daridorexant in adult and elderly subjects suffering from difficulties to sleep
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For woman of , the following is required:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Film-coated tablets administered orally, once daily in the evening
Drug: Daridorexant 10 mg
Film-coated tablets administered orally, once daily in the evening
Drug: Daridorexant 25 mg
Film-coated tablets administered orally, once daily in the evening
Drug: Daridorexant 50 mg
Film-coated tablets administered orally, once daily in the evening
Drug: Placebo
Film-coated tablets administered orally, once daily in the evening
Drug: Daridorexant 25 mg
Daridorexant 10 mg film-coated tablets
Daridorexant 25 mg film-coated tablets
Daridorexant 50 mg film-coated tablets
Matching placebo film-coated tablets
Total no. of Subjects With at Least One TEAE
The primary objective of the study was to assess the long-term safety and tolerability of 10, 25 and 50 mg daridorexant. The total no. of subjects with at least one TEAE is presented here; no statistical analysis was conducted. The full set of safety data is available in the Section "Adverse events".
Time frame: TEAEs (AEs that started or worsened during the double-blind study period up to 30 days after double-blind study treatment end date) are reported. Total duration: up to 44 weeks.
Ninety-four sites in 14 countries (Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Hungary, South Korea, Poland, Spain, Sweden, Switzerland, and the US) enrolled and randomized subjects.
| Milestone | Daridorexant 10 mg | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | ExPlacebo/Daridorexant 25 mg |
|---|---|---|---|---|---|
| Started | 142 | 268 | 137 | 128 | 126 |
| Completed | 99 | 190 | 93 | 78 | 90 |
| Not completed | 43 | 78 | 44 | 50 | 36 |
| Withdrew: Other | 12 | 12 | 12 | 7 | 8 |
| Withdrew: Lack of efficacy | 15 | 29 | 13 | 29 | 10 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 10 | 9 | 6 | 6 |
| Withdrew: Withdrawal by subject | 12 | 23 | 8 | 8 | 9 |
| Withdrew: Lost to follow-up | 1 | 4 | 2 | 0 | 3 |
The primary objective of the study was to assess the long-term safety and tolerability of 10, 25 and 50 mg daridorexant. The total no. of subjects with at least one TEAE is presented here; no statistical analysis was conducted. The full set of safety data is available in the Section "Adverse events".
| Participants | Daridorexant 10 mg | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | ExPlacebo / Daridorexant 25 mg |
|---|---|---|---|---|---|
| Total no. of Subjects With at Least One TEAE | 53 | 103 | 55 | 45 | 48 |
Collected over All treatment-emergent SAEs and AEs are reported.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Daridorexant 10 mg | 1/142 (0.7%) | 5/142 (3.5%) | 7/142 (4.9%) |
| Daridorexant 25 mg | 1/268 (0.4%) | 12/268 (4.5%) | 15/268 (5.6%) |
| Daridorexant 50 mg | 0/137 (0%) | 7/137 (5.1%) | 12/137 (8.8%) |
| Placebo | 0/128 (0%) | 2/128 (1.6%) | 6/128 (4.7%) |
| Ex-Placebo Daridorexant 25 mg | 0/126 (0%) | 4/126 (3.2%) | 11/126 (8.7%) |
| Event | Daridorexant 10 mg | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | Ex-Placebo Daridorexant 25 mg |
|---|---|---|---|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/142 | 0/268 | 0/137 | 0/128 | 0/126 |
| Aortic valve disease mixedCardiac disorders | 0/142 | 0/268 | 0/137 | 0/128 | 1/126 |
| Chest discomfortGeneral disorders | 0/142 | 0/268 | 0/137 | 0/128 | 1/126 |
| AppendicitisInfections and infestations | 0/142 | 0/268 | 0/137 | 0/128 | 1/126 |
| Cerebrovascular accidentNervous system disorders | 1/142 | 0/268 | 0/137 | 0/128 | 1/126 |
| Head injuryInjury, poisoning and procedural complications | 0/142 | 0/268 | 0/137 | 1/128 | 0/126 |
| Subdural haematomaInjury, poisoning and procedural complications | 0/142 | 0/268 | 0/137 | 1/128 | 0/126 |
| DepressionPsychiatric disorders | 0/142 | 0/268 | 0/137 | 1/128 | 0/126 |
| Suicidal ideationPsychiatric disorders | 0/142 | 0/268 | 0/137 | 1/128 | 0/126 |
| DiverticulitisInfections and infestations | 0/142 | 2/268 | 1/137 | 0/128 | 0/126 |
| Event | Daridorexant 10 mg | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | Ex-Placebo Daridorexant 25 mg |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/142 | 15/268 | 12/137 | 6/128 | 11/126 |
These are the participants included in the FAS. The discrepancy with previous table (Participant Flow) is due to 3 subjects on FAS (2 on daridorexant 25 mg and 1 on ex-placebo/ daridorexant 25 mg) not starting DB treatment.
| Age, Categorical(Participants) | Daridorexant 10 mg | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | ExPlacebo/Daridorexant 25 mg | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 80 | 166 | 83 | 70 | 70 | 469 |
| >=65 years | 62 | 104 | 54 | 58 | 57 | 335 |
| Age, Continuous(years) | Daridorexant 10 mg | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | ExPlacebo/Daridorexant 25 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 58.6 ± 12.8 | 57.6 ± 14.1 | 56.9 ± 13.6 | 59.2 ± 12.6 | 56.5 ± 15.5 | 57.7 ± 13.8 |
| Sex: Female, Male(Participants) | Daridorexant 10 mg | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | ExPlacebo/Daridorexant 25 mg | Total |
|---|---|---|---|---|---|---|
| Female | 103 | 199 | 98 | 92 | 83 | 575 |
| Male | 39 | 71 | 39 | 36 | 44 | 229 |
| Race/Ethnicity, Customized(Participants) | Daridorexant 10 mg | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | ExPlacebo/Daridorexant 25 mg | Total |
|---|---|---|---|---|---|---|
| Black or African American | 6 | 19 | 15 | 8 | 7 | 55 |
| American Indian or Alaska Native | 2 | 0 | 1 | 0 | 0 | 3 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 5 | 8 | 0 | 2 | 5 | 20 |
| White | 128 | 243 | 121 | 115 | 115 | 722 |
| Other | 0 | 0 | 0 | 2 | 0 | 2 |
| Not permitted as per legislation/regulation | 1 | 0 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Daridorexant 10 mg | Daridorexant 25 mg | Daridorexant 50 mg | Placebo | ExPlacebo/Daridorexant 25 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 33 | 19 | 10 | 13 | 81 |
| Not Hispanic or Latino | 135 | 237 | 118 | 118 | 114 | 722 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 |
| Not permitted as per legislation/regulation | 1 | 0 | 0 | 0 | 0 | 1 |
Showing the first 100 of 106 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Feb 2021, 28 months.
Results were first posted in Mar 2022, 1 year after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 28 months is above that.
Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daridorexant
Sleep Initiation and Maintenance Disorders →
Idorsia Pharmaceuticals Ltd. →